MDLZ — Mondelez International, Inc.

Sell-side sentiment is clearly constructive: the coverage breakdown is 32 Buy / 8 Hold / 2 Sell, and following the Q2 2026 beat (adjusted EPS $0.73 vs. $0.68 consensus on revenue of $9.36B vs. $9.21B expected), JPMorgan, Barclays and TD Cowen all pushed targets higher, leaving the consensus target at $70.29 and the recent average at $71.20. Management also raised the quarterly dividend to $0.52, and the stock's 6-month return of +13.75% (as of 2026-09-13) shows the market has partly bought the recovery story. The nuance: 1-month return is just +0.42% and 3-month is -0.87%, so the bullishness lives mostly in analyst ratings and post-earnings revisions rather than in fresh price momentum.

Revenue is growing but decelerating: YoY growth ran +9.3% in Q4 2025 and +8.2% in Q1 2026 before cooling to +4.1% in Q2 2026 ($9.355B vs. $8.984B). Margins, not revenue, are the real story. Gross margin fell from ~37-39% in the 2023 quarters (Q3 2023: 38.7%; Q4 2023: 37.3%) to ~26-33% through 2025 and into Q1 2026 (Q3 2025: 26.8%; Q1 2026: 27.8%), and TTM operating margin is 11.4% ($4.53B on $39.68B of revenue) — a genuine input-cost-driven compression, not a demand problem. Be careful with the two most eye-catching quarters: Q1 2024 (29.4% operating margin, 51% gross margin) and Q2 2026 (20.8% operating margin, 42.6% gross margin) are both far outside the run-rate and Q2 2026's GAAP EPS of $1.20 against adjusted EPS of $0.73 confirms a large (~$0.47/share, roughly $800M pre-tax) one-off gain is embedded in the reported figures. Reported EPS is correspondingly noisy ($0.31 in Q1 2025 to $1.30 in Q4 2024 to $1.20 in Q2 2026). Cash generation is lumpy but improving on a TTM basis: TTM FCF of $3.085B (Q3 2025 through Q2 2026) vs. $2.861B in the prior TTM window, with the December quarter ($1.999B FCF in Q4 2025) carrying the year.

Fair-to-modestly-cheap, with a caveat. As of 2026-09-13, the trailing P/E of 22.96x sits below the 5-year average of 24.25x, and P/S of 2.01x is a 22% discount to the 5-year average of 2.58x — the deterministic model's "Cheap vs. its own history" label rests on exactly those two comparisons. Forward math is more modest: at $62.44 against next-FY consensus EPS of $3.049, the stock trades at ~20.5x forward earnings, which is a reasonable but not distressed multiple for a low-beta (0.40), 3.46%-yielding staple growing the top line ~4%. Two things temper the "cheap" read: the trailing P/E is flattered by the Q2 2026 one-off gain (core trailing EPS is closer to ~$2.26, i.e. ~27.6x), and EV/EBITDA of 16.35x is not cheap for a food company with a 5.1% ROIC. PEG of -15.84 is noise, not signal. Bottom line: the discount to history is real but it is payment for a cocoa-driven margin trough and slowing growth, not a free lunch.

The market is pricing MDLZ at roughly 20.5x forward EPS versus a 5-year average trailing multiple of 24.25x — effectively saying it will not pay for margin recovery until it sees it. That cuts both ways. If cocoa costs ease and EPS climbs toward $3.30-3.50 over the next two years, a still-conservative 20x multiple puts the stock at $66-70; at the historical 24x, you would be looking at $79-84. If margins stay at the trough, 20x on $3.05 is roughly $62 — right where the stock is, meaning the current price already assumes "no recovery, no deterioration." The trap to avoid is extrapolating Q2 2026's $1.20 GAAP quarter: adjusted EPS was $0.73, so a naive annualization of the headline number massively overstates earning power. Watch the Q3 2026 print (Oct 27, 2026, consensus ~$0.72) for the first clean read on whether gross margin is actually inflecting off the ~27-28% base.

As of 2026-09-13, MDLZ is range-bound and directionless, not set up for either an oversold bounce or a momentum chase. RSI(14) of 50.97 is dead neutral; price of $62.44 sits 0.46% below the 20-day SMA, 1.13% above the 50-day and 5.43% above the 200-day — a mild uptrend that has stalled in the last quarter (3-month return -0.87% versus +13.75% over six months). With the 52-week range at $51.20-$66.65, the stock is in the upper-middle of its band and about 6.3% below the 52-week high. Entry implication: this is a scale-in name, not a breakout name. Accumulating near the 50-day (~$61.7) or on a pullback toward $60 offers better risk/reward than buying into $66, and a decisive break below the 200-day (~$59.2) would signal the market is losing patience with the margin-recovery thesis.

• Cocoa and agricultural input costs: the single biggest swing factor. The brief flags 'severe historic cocoa input cost inflation' as the primary drag on gross and operating margin, and the data confirms it — gross margin fell from ~37-39% in 2023 to ~27-28% in the four quarters through Q1 2026. Any sustained relief in cocoa futures flows into 2027 hedges/contracts and would be the largest single positive catalyst for earnings.
• Consumer elasticity and private-label substitution: after multiple years of price-led growth in North America and Europe, volume/mix is the risk. Management is leaning on North American share gains and emerging-market volume, but cumulative inflation fatigue can push shoppers toward cheaper private-label snacks.
• FX translation: MDLZ books the majority of revenue outside the US, so a stronger dollar mechanically shrinks reported revenue and EPS even when local demand is fine — a persistent, uncontrollable source of reported-number volatility.
• Rates and defensive rotation: with a beta of 0.40 and a 3.46% dividend yield, MDLZ trades as a bond-proxy staple. Falling rates support the relative valuation and the dividend; rising rates do the opposite, particularly given the stock's ~86% dividend payout versus TTM free cash flow.
• Health and wellness / GLP-1 demand shifts: longer-term structural pressure on sugary and confectionery categories that no single quarter's data will reveal but that caps the terminal multiple the market is willing to pay for chocolate and biscuit volumes.
• Balance-sheet optics: a 0.599 current ratio and 0.395 quick ratio leave MDLZ reliant on continuous capital-markets access to fund working capital — normal for the sector, but it does mean the ratio screener will keep penalizing the stock until liquidity metrics improve.

• Q3 2026 earnings on 2026-10-27 (consensus EPS ~$0.72) — the first clean read on whether gross margin is inflecting off the ~27-28% base and whether holiday-season inventory builds and emerging-market volumes are holding up.
• Cocoa cost normalization: if input costs roll over, the margin recovery would be large in absolute terms (a return to mid-30s gross margin on ~$40B of revenue is worth well over $1.5B of gross profit versus the current trough) and would force upward EPS revisions across the street.
• Continued dividend growth and buybacks: the raise to $0.52/quarter demonstrates confidence in cash generation and underpins the 3.46% yield, which is a core part of the total-return case for income-oriented holders.
• Portfolio reshaping / M&A: the large one-off gain embedded in Q2 2026 (GAAP EPS $1.20 vs. adjusted $0.73) points to transaction activity. Further divestitures of lower-margin or slower-growth brands would be read positively if proceeds fund buybacks or debt reduction.
• Further analyst target revisions: with the consensus target at $70.29 and the recent average at $71.20 versus a $62.44 share price, continued estimate momentum from the post-Q2 revisions could pull the stock toward the low end of the targets ($65).

• Cocoa costs stay elevated for longer than hedged: if the trough margin of ~9-10% underlying operating margin persists, ROIC stays near 5.1% — below any reasonable cost of capital — and the 'cheap vs. its own history' P/S of 2.01x is simply the correct price, not a discount.
• Volume/price mix deterioration: revenue growth decelerated from +8.2% in Q1 2026 to +4.1% in Q2 2026, and if that deceleration continues it will be hard to grow into the current multiple without further price increases that risk pushing consumers to private label.
• Earnings quality and one-off distortion: reported Q2 2026 GAAP EPS of $1.20 versus $0.73 adjusted means headline earnings overstate the underlying run-rate by roughly $0.47/share; a market that anchors on the headline number is mispricing the core business.
• Dividend coverage and liquidity: TTM FCF of $3.085B against roughly $2.65B of annual dividend cost leaves thin cover, and a current ratio of 0.599 / quick ratio of 0.395 with $21.59B of current liabilities versus $12.94B of current assets means there is little balance-sheet cushion if cash generation dips.
• Currency translation and geopolitical/trade friction across a globally distributed manufacturing and distribution footprint, which can hit reported revenue and margins regardless of underlying local demand.

MDLZ is a genuinely good branded-snacking franchise (Oreo, Cadbury, Toblerone, belVita) with 4% top-line growth, a 0.40 beta and a 3.46% dividend, currently priced at ~20.5x forward earnings because its gross margin is running roughly 800-1,000bp below 2023 levels on cocoa costs. That is a reasonable place to own a defensive staple, but it is not a fat pitch: ROIC of 5.1% is below cost of capital today, TTM FCF barely covers the dividend, the latest GAAP quarter is inflated by a one-off gain, and revenue growth is decelerating. I would treat $62 as roughly fair with optionality to the upside if cocoa normalizes, and I would want the Oct 27, 2026 print to confirm margin direction before adding aggressively.

I applied a 21.5x forward P/E to next-FY consensus EPS of $3.049, giving $65.55, and rounded to $66 — the 21.5x is a deliberate discount to MDLZ's own 24.25x five-year average trailing P/E (justified by decelerating revenue growth of +4.1% in Q2 2026 and the unresolved cocoa overhang) but a premium to the ~20.5x the market currently pays (justified by the 0.40 beta, the 3.46% dividend yield and the margin-recovery optionality if input costs normalize). Cross-checked against cash: $66 implies a ~3.7% free-cash-flow yield on TTM FCF of $3.085B, roughly one point of coverage above the current dividend yield, which is about as thin as I am willing to underwrite for a staple with a 0.599 current ratio.